Xenoport

About:

XenoPort is a biopharmaceutical company that develops a portfolio of product candidates to treat neurological disorders.

Website: http://xenoport.com

Twitter/X: xenoport

Top Investors: Notable Capital, Frazier Healthcare Partners, Venrock, ARCH Venture Partners, Skyline Ventures

Description:

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.